Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02202759 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Study Title
A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction (NCT02202759)

Trial Description
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 (Indusatumab vedotin) in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.

This trial is sponsored by Millennium Pharmaceuticals [1]

Study Data

  • Condition: Stomach Cancer or Gastroesophageal Junction
  • Interventions:
    • Drugs used in this trial
      • MLN0264 (Indusatumab vedotin)
  • Phase: II
  • Estimated Enrollment: 81
  • Start: July 2014
  • Estimated Completion: September 2018
  • Last verified: July 2015

Study Schematic 

NCT02202785 (Clinical Trial/ Indusatumab vedotin / MLN0264)

Click here to Return to Drug map


Last Editorial review: July 17, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar